person · Reporting owner

Smither John W

Disclosed activity across 10 companies

Tapewire entity: 26570
SEC CIK: 0001559583

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Achaogen, Inc.AKAO · Entity 158957	Director	June 05, 2018	June 07, 2018
Arcutis Biotherapeutics, Inc.ARQT · Entity 4236	Chief Financial Officer	February 13, 2024	February 15, 2024
Attovia Therapeutics, Inc.ATTO · Entity 4984	Director	August 04, 2026	August 04, 2026
GENELUX CorpGNLX · Entity 1116	Director	July 01, 2026	July 02, 2026
MBX Biosciences, Inc.MBX · Entity 4247	Chief Financial Officer	August 03, 2026	August 04, 2026
NewAmsterdam Pharma Co N.V.NAMS · Entity 1826	Director	September 04, 2026	September 09, 2026
Principia Biopharma Inc.PRNB · Entity 146423	Director	February 19, 2019	February 21, 2019
Sienna Biopharmaceuticals, Inc.SNNA · Entity 154554	Chief Financial Officer	January 01, 2019	January 03, 2019
eFFECTOR Therapeutics, Inc.EFTR · Entity 89916	Director	June 22, 2023	June 23, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Achaogen, Inc.

Report date June 05, 2018 · Filed June 07, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.07 · Expires 2028-06-05	Direct	15,000	Reported balance After 2018-06-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-06-05 · Grant · Acquired 15,000 · Balance 15,000 F1: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date.

Arcutis Biotherapeutics, Inc.

Report date February 13, 2024 · Filed February 15, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	11,365	Ending reported balance After 2024-02-13 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2024-02-13 · Grant · Acquired 2,793 · Balance 2,793 F1: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on February 27, 2020, and received in exchange for the option, these Restricted Stock Units ("RSUs") that vest in four equal quarterly installments commencing May 1, 2024. Row 2 · 2024-02-13 · Grant · Acquired 8,572 · Balance 11,365 F2: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2021, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.61 · Expires 2025-03-31	Direct	0	Reported balance After 2024-02-13 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-02-13 · Disposition to issuer · Disposed 8,379 · Balance 0 F1: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on February 27, 2020, and received in exchange for the option, these Restricted Stock Units ("RSUs") that vest in four equal quarterly installments commencing May 1, 2024. F4: This option is fully vested.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.44 · Expires 2025-03-31	Direct	0	Reported balance After 2024-02-13 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-02-13 · Disposition to issuer · Disposed 25,718 · Balance 0 F2: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2021, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024. F5: This option is fully vested.
Common StockSEC Table I · non-derivative	IndirectBy Trust	141,392	Reported balance Holding disclosure · report date 2024-02-13 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 141,392 F3: The securities are held of record by The 1994 Smither Family Trust, as Amended and Restated in 2014, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

Filing footnotes · ownership attribution and instrument terms

F1: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on February 27, 2020, and received in exchange for the option, these Restricted Stock Units ("RSUs") that vest in four equal quarterly installments commencing May 1, 2024.

F2: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2021, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024.

F3: The securities are held of record by The 1994 Smither Family Trust, as Amended and Restated in 2014, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

F4: This option is fully vested.

F5: This option is fully vested.

Attovia Therapeutics, Inc.

Report date August 04, 2026 · Filed August 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.29 · Expires 2036-07-01	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-08-04 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: The option vests over a three-year period, with 33% vesting on July 2, 2027, an additional 33% on July 2, 2028 and the final 33% on July 2, 2029, subject to continued service to the Issuer through each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests over a three-year period, with 33% vesting on July 2, 2027, an additional 33% on July 2, 2028 and the final 33% on July 2, 2029, subject to continued service to the Issuer through each vesting date.

GENELUX Corp

Report date July 01, 2026 · Filed July 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	91,403	Reported balance After 2026-07-01 transaction · row 1 1 source row Row 1 · 2026-07-01 · Sale · Disposed 12,000 · Balance 91,403 F1: Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units. F2: The weighted average sale price for the transaction reported was $2.9082, and the range of prices were between $2.87 and $2.93. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units.

F2: The weighted average sale price for the transaction reported was $2.9082, and the range of prices were between $2.87 and $2.93. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

MBX Biosciences, Inc.

Report date August 03, 2026 · Filed August 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	28,000	Reported balance After 2026-08-03 transaction · row 1 1 source row Row 1 · 2026-08-03 · Grant · Acquired 28,000 · Balance 28,000 F1: Represents the grant of restricted stock units ("RSUs"). 25% of the shares subject to the RSU grant will vest annually over four years, on each July 13, 2027, 2028, 2029 and 2030, subject to continued service on each such vesting date.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.41 · Expires 2036-08-03	Direct	130,000	Reported balance After 2026-08-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-08-03 · Grant · Acquired 130,000 · Balance 130,000 F2: The options will vest and become exercisable with 25% of the shares subject to the award vesting on July 13, 2027 and the remainder vesting in 36 equal monthly installments thereafter, subject to continued service on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the grant of restricted stock units ("RSUs"). 25% of the shares subject to the RSU grant will vest annually over four years, on each July 13, 2027, 2028, 2029 and 2030, subject to continued service on each such vesting date.

F2: The options will vest and become exercisable with 25% of the shares subject to the award vesting on July 13, 2027 and the remainder vesting in 36 equal monthly installments thereafter, subject to continued service on each such vesting date.

NewAmsterdam Pharma Co N.V.

Report date September 04, 2026 · Filed September 09, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	8,760	Reported balance After 2026-09-04 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-09-04 · Sale · Disposed 1,600 · Balance 8,760 F1: Reported transaction reflects a sale of ordinary shares to generate proceeds to satisfy the Reporting Person's tax obligations in connection with the prior vesting of restricted stock units. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.24 to $25.37 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. F3: Includes 8,040 ordinary shares subject to restricted stock unit awards that remain subject to vesting.

Filing footnotes · ownership attribution and instrument terms

F1: Reported transaction reflects a sale of ordinary shares to generate proceeds to satisfy the Reporting Person's tax obligations in connection with the prior vesting of restricted stock units.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.24 to $25.37 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

F3: Includes 8,040 ordinary shares subject to restricted stock unit awards that remain subject to vesting.

Principia Biopharma Inc.

Report date February 19, 2019 · Filed February 21, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.30 · Expires 2029-02-18	Direct	20,475	Reported balance After 2019-02-19 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-02-19 · Grant · Acquired 20,475 · Balance 20,475 F1: The stock option vests in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option vests in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.

Sienna Biopharmaceuticals, Inc.

Report date January 01, 2019 · Filed January 03, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	46,657	Reported balance After 2019-01-01 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2019-01-01 · Grant · Acquired 45,000 · Balance 46,657 F1: Award of restricted stock units ("RSUs") granted under the Issuer's 2017 Incentive Award Plan. Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting. The award vests as to twenty-five percent (25%) of the total number of RSUs on July 1, 2019, twenty-five percent (25%) of the total number of RSUs on January 1, 2020, and the remaining fifty percent (50%) of the total number of RSUs on the second anniversary, in each case, subject to the Reporting Person's continued employment or service relationship with the Issuer through the applicable vesting date. F2: Includes a total of 1,657 shares of the Issuer's common stock acquired pursuant to the Issuer's Employee Stock Purchase Plan.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.32 · Expires 2029-01-01	Direct	14,422	Reported balance After 2019-01-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-01-01 · Grant · Acquired 14,422 · Balance 14,422
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.32 · Expires 2029-01-01	Direct	22,500	Reported balance After 2019-01-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-01-01 · Grant · Acquired 22,500 · Balance 22,500 F4: Twenty percent (20%) of the shares subject to the option vest and become exercisable upon satisfaction of one performance-based milestone, forty percent (40%) of the shares vest and become exercisable upon satisfaction of a second performance-based milestone, and the remaining forty percent (40%) of the shares vest and become exercisable upon satisfaction of a third performance-based milestone, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.32 · Expires 2029-01-01	Direct	45,000	Reported balance After 2019-01-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-01-01 · Grant · Acquired 22,500 · Balance 45,000 F5: Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on July 1,2019, twenty-five percent (25%) of the shares vest and become exercisable on January 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	34,961	Reported balance Holding disclosure · report date 2019-01-01 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 34,961 F3: The shares are directly held by the 1994 Smither Family Trust, as Amended and Restated in 2014.

Filing footnotes · ownership attribution and instrument terms

F1: Award of restricted stock units ("RSUs") granted under the Issuer's 2017 Incentive Award Plan. Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting. The award vests as to twenty-five percent (25%) of the total number of RSUs on July 1, 2019, twenty-five percent (25%) of the total number of RSUs on January 1, 2020, and the remaining fifty percent (50%) of the total number of RSUs on the second anniversary, in each case, subject to the Reporting Person's continued employment or service relationship with the Issuer through the applicable vesting date.

F2: Includes a total of 1,657 shares of the Issuer's common stock acquired pursuant to the Issuer's Employee Stock Purchase Plan.

F3: The shares are directly held by the 1994 Smither Family Trust, as Amended and Restated in 2014.

F4: Twenty percent (20%) of the shares subject to the option vest and become exercisable upon satisfaction of one performance-based milestone, forty percent (40%) of the shares vest and become exercisable upon satisfaction of a second performance-based milestone, and the remaining forty percent (40%) of the shares vest and become exercisable upon satisfaction of a third performance-based milestone, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.

F5: Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on July 1,2019, twenty-five percent (25%) of the shares vest and become exercisable on January 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.

eFFECTOR Therapeutics, Inc.

Report date June 22, 2023 · Filed June 23, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2033-06-21	Direct	20,000	Reported balance After 2023-06-22 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-06-22 · Grant · Acquired 20,000 · Balance 20,000 F1: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest in full on the earlier to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest in full on the earlier to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Applied Molecular Transport Inc.

Report date December 27, 2023 · Filed December 28, 2023

Section 16 reporting ended · disclosed 2023-12-28. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.01 · Expires 2032-01-27	Direct	Reported balance After 2023-12-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-12-27 · Disposition to issuer · Disposed 60,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated as of September 21, 2023 (the "Merger Agreement"), by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc. and the Issuer, at the effective time of the merger, each outstanding option with an exercise price of $0.40 or more was cancelled effective as of the closing.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.13 · Expires 2033-05-24	Direct	Reported balance After 2022-05-24 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-05-24 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated as of September 21, 2023 (the "Merger Agreement"), by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc. and the Issuer, at the effective time of the merger, each outstanding option with an exercise price of $0.40 or more was cancelled effective as of the closing.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.34 · Expires 2033-06-14	Direct	Reported balance After 2023-12-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-12-27 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, this option was exchanged for an option covering 2,662 shares of Cyclo Common Stock.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger dated as of September 21, 2023 (the "Merger Agreement"), by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc. and the Issuer, at the effective time of the merger, each outstanding option with an exercise price of $0.40 or more was cancelled effective as of the closing.

F2: Pursuant to the terms of the Merger Agreement, this option was exchanged for an option covering 2,662 shares of Cyclo Common Stock.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 10, 2021 Filed Feb 12, 2021 22:32 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	SaleCommon Stock	750	$35.64	$26,730.00	Disclosure SEC source: 0001567619-21-003626 · doc1.xml · nonDerivative · entry 2 Smither John W · CIK 0001559583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,198 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 9,000 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document
February 10, 2021 Filed Feb 12, 2021 22:32 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	Exercise / conversionCommon Stock	750	$1.68	$1,260.45	Disclosure SEC source: 0001567619-21-003626 · doc1.xml · nonDerivative · entry 1 Smither John W · CIK 0001559583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,948 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 9,000 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document
February 01, 2021 Filed Feb 3, 2021 16:23 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	Exercise / conversionStock Option (Right to Buy) · Derivative	1,250	$0.00 Strike: $1.68	$0.00	Disclosure SEC source: 0001567619-21-002077 · doc1.xml · derivative · entry 4 Smither John W · CIK 0001559583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,232 Underlying: Common Stock · 1,250 shares Expires 2029-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document
February 01, 2021 Filed Feb 3, 2021 16:23 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	SaleCommon Stock	3,750	$35.00	$131,250.00	Disclosure SEC source: 0001567619-21-002077 · doc1.xml · nonDerivative · entry 3 Smither John W · CIK 0001559583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 89,965 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · ownership.nature: The securities are held of record by The 1994 Smither Family Trust, as Amended and Restated in 2014, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document
February 01, 2021 Filed Feb 3, 2021 16:23 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	SaleCommon Stock	1,250	$35.00	$43,750.00	Disclosure SEC source: 0001567619-21-002077 · doc1.xml · nonDerivative · entry 2 Smither John W · CIK 0001559583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,198 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 9,000 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document
February 01, 2021 Filed Feb 3, 2021 16:23 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	Exercise / conversionCommon Stock	1,250	$1.68	$2,100.75	Disclosure SEC source: 0001567619-21-002077 · doc1.xml · nonDerivative · entry 1 Smither John W · CIK 0001559583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 9,000 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document
January 19, 2021 Filed Jan 21, 2021 21:41 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	Exercise / conversionStock Option (Right to Buy) · Derivative	500	$0.00 Strike: $1.68	$0.00	Disclosure SEC source: 0001567619-21-001340 · doc1.xml · derivative · entry 4 Smither John W · CIK 0001559583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,482 Underlying: Common Stock · 500 shares Expires 2029-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document
January 19, 2021 Filed Jan 21, 2021 21:41 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	SaleCommon Stock	1,250	$30.00	$37,500.00	Disclosure SEC source: 0001567619-21-001340 · doc1.xml · nonDerivative · entry 3 Smither John W · CIK 0001559583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 93,715 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · ownership.nature: The securities are held of record by The 1994 Smither Family Trust, as Amended and Restated in 2014, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document
January 19, 2021 Filed Jan 21, 2021 21:41 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	SaleCommon Stock	500	$30.00	$15,000.00	Disclosure SEC source: 0001567619-21-001340 · doc1.xml · nonDerivative · entry 2 Smither John W · CIK 0001559583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,198 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 9,000 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document
January 19, 2021 Filed Jan 21, 2021 21:41 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	Exercise / conversionCommon Stock	500	$1.68	$840.30	Disclosure SEC source: 0001567619-21-001340 · doc1.xml · nonDerivative · entry 1 Smither John W · CIK 0001559583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 9,000 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document
December 14, 2020 Filed Dec 16, 2020 20:14 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	Exercise / conversionStock Option (Right to Buy) · Derivative	1,500	$0.00 Strike: $1.68	$0.00	Disclosure SEC source: 0001567619-20-021190 · doc1.xml · derivative · entry 4 Smither John W · CIK 0001559583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,982 Underlying: Common Stock · 1,500 shares Expires 2029-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document
December 14, 2020 Filed Dec 16, 2020 20:14 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	SaleCommon Stock	3,750	$30.00	$112,500.00	Disclosure SEC source: 0001567619-20-021190 · doc1.xml · nonDerivative · entry 3 Smither John W · CIK 0001559583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 94,965 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · ownership.nature: The securities are held of record by The 1994 Smither Family Trust, as Amended and Restated in 2014, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document
December 14, 2020 Filed Dec 16, 2020 20:14 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	SaleCommon Stock	1,500	$30.00	$45,000.00	Disclosure SEC source: 0001567619-20-021190 · doc1.xml · nonDerivative · entry 2 Smither John W · CIK 0001559583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,198 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 9,000 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. F3 · balance_after: Includes 1,323 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as follows: 1,176 shares on May 31, 2020 and 147 shares on November 30, 2020. Read SEC document
December 14, 2020 Filed Dec 16, 2020 20:14 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	Exercise / conversionCommon Stock	1,500	$1.68	$2,520.90	Disclosure SEC source: 0001567619-20-021190 · doc1.xml · nonDerivative · entry 1 Smither John W · CIK 0001559583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 9,000 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. F3 · balance_after: Includes 1,323 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as follows: 1,176 shares on May 31, 2020 and 147 shares on November 30, 2020. Read SEC document
September 29, 2020 Filed Oct 2, 2020 01:00 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	Exercise / conversionStock Option (Right to Buy) · Derivative	500	$0.00 Strike: $1.68	$0.00	Disclosure SEC source: 0001567619-20-017381 · doc1.xml · derivative · entry 4 Smither John W · CIK 0001559583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,482 Underlying: Common Stock · 500 shares Expires 2029-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document
September 29, 2020 Filed Oct 2, 2020 01:00 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	SaleCommon Stock	1,250	$30.00	$37,500.00	Disclosure SEC source: 0001567619-20-017381 · doc1.xml · nonDerivative · entry 3 Smither John W · CIK 0001559583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 98,715 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · ownership.nature: The securities are held of record by The 1994 Smither Family Trust, as Amended and Restated in 2014, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document
September 29, 2020 Filed Oct 2, 2020 01:00 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	SaleCommon Stock	500	$30.00	$15,000.00	Disclosure SEC source: 0001567619-20-017381 · doc1.xml · nonDerivative · entry 2 Smither John W · CIK 0001559583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,875 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 9,000 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document
September 29, 2020 Filed Oct 2, 2020 01:00 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	Exercise / conversionCommon Stock	500	$1.68	$840.30	Disclosure SEC source: 0001567619-20-017381 · doc1.xml · nonDerivative · entry 1 Smither John W · CIK 0001559583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 9,000 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document
June 11, 2020 Filed Jun 15, 2020 19:15 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	Exercise / conversionStock Option (Right to Buy) · Derivative	14,875	$0.00 Strike: $1.68	$0.00	Disclosure SEC source: 0001567619-20-012131 · doc1.xml · derivative · entry 2 Smither John W · CIK 0001559583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,080 Underlying: Common Stock · 14,875 shares Expires 2029-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects cash exercise of stock option without the disposition of the underlying shares. F3 · derivative.exercise_date: The option vests as to 1/4 of the total shares on May 1, 2020, and then 1/48 of the total shares vest monthly thereafter, with 100% of the total shares vested and exercisable on May 1, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document
June 11, 2020 Filed Jun 15, 2020 19:15 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	Exercise / conversionCommon Stock	14,875	$1.68	$24,998.93	Disclosure SEC source: 0001567619-20-012131 · doc1.xml · nonDerivative · entry 1 Smither John W · CIK 0001559583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects cash exercise of stock option without the disposition of the underlying shares. F2 · balance_after: Includes 9,000 Restricted Stock Units ("RSUs"). The RSUs vest annually in equal installments over a period of 4 years commencing on the grant date, so that 100% of the RSUs become fully vested on February 27, 2024. Read SEC document
February 27, 2020 Filed Mar 4, 2020 02:09 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	GrantStock Option (Right to Buy) · Derivative	12,000	$0.00 Strike: $27.61	$0.00	Disclosure SEC source: 0001567619-20-005550 · doc1.xml · derivative · entry 2 Smither John W · CIK 0001559583 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-02-27 F3 · derivative.exercise_date: The shares subject to the stock option vest in equal monthly installments over a period of 48 months commencing on the grant date so that 100% of the shares become fully vested and exercisable on February 27, 2024. Read SEC document
February 27, 2020 Filed Mar 4, 2020 02:09 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	GrantCommon Stock	9,000	$0.00	$0.00	Disclosure SEC source: 0001567619-20-005550 · doc1.xml · nonDerivative · entry 1 Smither John W · CIK 0001559583 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,965 F1 · shares: Grant of Restricted Stock Units ("RSU"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. F2 · balance_after: Includes 9,000 RSUs. The RSUs vest annually in equal installments over a period of 4 years commencing on the grant date, so that 100% of the RSUs become fully vested on February 27, 2024. Read SEC document
February 19, 2019 Filed Feb 21, 2019 18:07 UTC	Principia Biopharma Inc. PRNB · Entity 146423	GrantDirector Stock Option (right to buy) · Derivative	20,475	$0.00 Strike: $30.30	$0.00	Disclosure SEC source: 0001209191-19-012249 · doc4.xml · derivative · entry 1 Smither John W · CIK 0001559583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,475 Underlying: Common Stock · 20,475 shares Expires 2029-02-18 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document
January 01, 2019 Filed Jan 3, 2019 18:19 UTC	Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554	GrantStock Options (Right to buy) · Derivative	22,500	$0.00 Strike: $2.32	$0.00	Disclosure SEC source: 0001562180-19-000149 · primarydocument.xml · derivative · entry 5 Smither John W · CIK 0001559583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 22,500 shares Expires 2029-01-01 F5 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on July 1,2019, twenty-five percent (25%) of the shares vest and become exercisable on January 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document
January 01, 2019 Filed Jan 3, 2019 18:19 UTC	Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554	GrantStock Options (Right to buy) · Derivative	22,500	$0.00 Strike: $2.32	$0.00	Disclosure SEC source: 0001562180-19-000149 · primarydocument.xml · derivative · entry 4 Smither John W · CIK 0001559583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2029-01-01 F4 · derivative.exercise_date: Twenty percent (20%) of the shares subject to the option vest and become exercisable upon satisfaction of one performance-based milestone, forty percent (40%) of the shares vest and become exercisable upon satisfaction of a second performance-based milestone, and the remaining forty percent (40%) of the shares vest and become exercisable upon satisfaction of a third performance-based milestone, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document
January 01, 2019 Filed Jan 3, 2019 18:19 UTC	Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554	GrantStock Options (Right to buy) · Derivative	14,422	$0.00 Strike: $2.32	$0.00	Disclosure SEC source: 0001562180-19-000149 · primarydocument.xml · derivative · entry 3 Smither John W · CIK 0001559583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,422 Underlying: Common Stock · 14,422 shares Expires 2029-01-01 Read SEC document
January 01, 2019 Filed Jan 3, 2019 18:19 UTC	Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554	GrantCommon Stock	45,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-19-000149 · primarydocument.xml · nonDerivative · entry 1 Smither John W · CIK 0001559583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,657 F1 · price: Award of restricted stock units ("RSUs") granted under the Issuer's 2017 Incentive Award Plan. Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting. The award vests as to twenty-five percent (25%) of the total number of RSUs on July 1, 2019, twenty-five percent (25%) of the total number of RSUs on January 1, 2020, and the remaining fifty percent (50%) of the total number of RSUs on the second anniversary, in each case, subject to the Reporting Person's continued employment or service relationship with the Issuer through the applicable vesting date. F2 · balance_after: Includes a total of 1,657 shares of the Issuer's common stock acquired pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document
July 15, 2018 Filed Jul 17, 2018 20:36 UTC	Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554	GrantStock Options (Right to buy) · Derivative	20,000	$0.00 Strike: $16.90	$0.00	Disclosure SEC source: 0001562180-18-003324 · primarydocument.xml · derivative · entry 1 Smither John W · CIK 0001559583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-07-15 Read SEC document
June 05, 2018 Filed Jun 7, 2018 18:55 UTC	Achaogen, Inc. AKAO · Entity 158957	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $12.07	$0.00	Disclosure SEC source: 0001140361-18-027771 · doc1.xml · derivative · entry 1 Smither John W · CIK 0001559583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-05 F1 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document
April 16, 2018 Filed Apr 18, 2018 18:31 UTC	Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554	GrantStock Option (Right to Buy) · Derivative	170,000	$0.00 Strike: $19.59	$0.00	Disclosure SEC source: 0001562180-18-001911 · primarydocument.xml · derivative · entry 1 Smither John W · CIK 0001559583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2028-04-16 F1 · derivative.exercise_date: The underlying shares subject to the option will vest as follows: i) 20,000 shares subject to the option vest and become exercisable upon satisfaction of a performance-based milestone and ii) 150,000 shares subject to the option vest and become exercisable with respect to 25% of 150,000 shares on the first anniversary measured from April 16, 2018, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document
June 14, 2017 Filed Jun 16, 2017 17:48 UTC	Achaogen, Inc. AKAO · Entity 158957	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $22.11	$0.00	Disclosure SEC source: 0001140361-17-025399 · doc1.xml · derivative · entry 1 Smither John W · CIK 0001559583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-14 F1 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual meeting of stockholders to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.